Junichi Yoshikawa
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Junichi Yoshikawa has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
- Hajime Kihara
Department of Internal Medicine, Kihara Cardiovascular Clinic, Asahikawa, Japan.
2 shared publications - Hiroki Oe
Center of Ultrasonic Diagnostics, Okayama University Hospital, Okayama, Japan
2 shared publications - Hiroshi Ito
Department of Hospital Medicine, University of Tsukuba Hospital, Tsukuba, Ibaraki, Japan
2 shared publications - Kazufumi Nakamura
Department of Cardiovascular Medicine, Shimane University Faculty of Medicine, Izumo, Japan
2 shared publications - Kenei Shimada
Department of Internal Medicine and Cardiology, Osaka City University Medical School, Osaka, Japan
2 shared publications - Kumiko Hirata
Department of Cardiovascular Medicine, Wakayama Medical University, Wakayama, Japan
2 shared publications
Latest Publications
- Open Access
- 19 June 2015
- Published by Springer Nature in Cardiovascular Diabetology
- Vol. 14 (1) , 83
Comparison of effects of sitagliptin and voglibose on left ventricular diastolic dysfunction in patients with type 2 diabetes: results of the 3D trial
Left ventricular (LV) diastolic dysfunction is frequently observed in patients with type 2 diabetes. Dipeptidyl peptidase-4 inhibitor (DPP-4i) attenuates postprandial hyperglycemia (PPH) and may have cardio-protective effects. It remains unclear whether DPP-4i improves LV diastolic function in patients with type 2 diabetes, and, if so, it is attributable to the attenuation of PPH or to a direct cardiac effect of DPP-4i. We compared the effects of the DPP-4i, sitagliptin, and the alpha-glucosidase inhibitor, voglibose, on LV diastolic function in patients with type 2 diabetes. We conducted a prospective, randomized, open-label, multicenter study of 100 diabetic patients with LV diastolic dysfunction. Patients received sitagliptin (50 mg/day) or voglibose (0.6 mg/day). The primary endpoints were changes in the e’ velocity and E/e’ ratio from baseline to 24 weeks later. The secondary efficacy measures included HbA1c, GLP-1, lipid profiles, oxidative stress markers and inflammatory markers. The study was completed with 40 patients in the sitagliptin group and 40 patients in the voglibose group. There were no significant changes in the e’ velocity and E/e’ ratio from baseline to 24 weeks later in both groups. However, analysis of covariance demonstrated that pioglitazone use is an independent factor associated with changes in the e’ and E/e’ ratio. Among patients not using pioglitazone, e’ increased and the E/e’ ratio decreased in both the sitagliptin and voglibose groups. GLP-1 level increased from baseline to 24 weeks later only in the sitagliptin group (4.8 ± 4.7 vs. 7.3 ± 5.5 pmol/L, p < 0.05). The reductions in HbA1c and body weight were significantly greater in the sitagliptin group than in the voglibose group (−0.7 ± 0.6 % vs. −0.3 ± 0.4, p < 0.005; −1.3 ± 3.2 kg vs. 0.4 ± 2.8 kg, p < 0.05, respectively). There were no changes in lipid profiles and inflammatory markers in both groups. Our trial showed that sitagliptin reduces HbA1c levels more greatly than voglibose does, but that neither was associated with improvement in the echocardiographic parameters of LV diastolic function in patients with diabetes. Registered at http://www.umin.ac.jp under UMIN000003784
- 19 June 2015
- Published by Springer Nature in Cardiovascular Diabetology
- Vol. 14 (1) , 83
Open AccessComparison of effects of sitagliptin and voglibose on left ventricular diastolic dysfunction in patients with type 2 diabetes: results of the 3D trial
Left ventricular (LV) diastolic dysfunction is frequently observed in patients with type 2 diabetes. Dipeptidyl peptidase-4 inhibitor (DPP-4i) attenuates postprandial hyperglycemia (PPH) and may have cardio-protective effects. It remains unclear whether DPP-4i improves LV diastolic function in patients with type 2 diabetes, and, if so, it is attributable to the attenuation of PPH or to a direct cardiac effect of DPP-4i. We compared the effects of the DPP-4i, sitagliptin, and the alpha-glucosidase inhibitor, voglibose, on LV diastolic function in patients with type 2 diabetes. We conducted a prospective, randomized, open-label, multicenter study of 100 diabetic patients with LV diastolic dysfunction. Patients received sitagliptin (50 mg/day) or voglibose (0.6 mg/day). The primary endpoints were changes in the e’ velocity and E/e’ ratio from baseline to 24 weeks later. The secondary efficacy measures included HbA1c, GLP-1, lipid profiles, oxidative stress markers and inflammatory markers. The study was completed with 40 patients in the sitagliptin group and 40 patients in the voglibose group. There were no significant changes in the e’ velocity and E/e’ ratio from baseline to 24 weeks later in both groups. However, analysis of covariance demonstrated that pioglitazone use is an independent factor associated with changes in the e’ and E/e’ ratio. Among patients not using pioglitazone, e’ increased and the E/e’ ratio decreased in both the sitagliptin and voglibose groups. GLP-1 level increased from baseline to 24 weeks later only in the sitagliptin group (4.8 ± 4.7 vs. 7.3 ± 5.5 pmol/L, p < 0.05). The reductions in HbA1c and body weight were significantly greater in the sitagliptin group than in the voglibose group (−0.7 ± 0.6 % vs. −0.3 ± 0.4, p < 0.005; −1.3 ± 3.2 kg vs. 0.4 ± 2.8 kg, p < 0.05, respectively). There were no changes in lipid profiles and inflammatory markers in both groups. Our trial showed that sitagliptin reduces HbA1c levels more greatly than voglibose does, but that neither was associated with improvement in the echocardiographic parameters of LV diastolic function in patients with diabetes. Registered at http://www.umin.ac.jp under UMIN000003784
- Open Access
- 30 July 2014
- Published by Springer Nature in Cardiovascular Diabetology
- Vol. 13 (1) , 1-10
DPP-4 inhibitor and alpha-glucosidase inhibitor equally improve endothelial function in patients with type 2 diabetes: EDGE study
Alpha glucosidase inhibitor (GI) attenuates postprandial hyperglycemia (PPH) and reduces the risk of cardiovascular events in patients with impaired glucose tolerance or type 2 diabetes. Dipeptidyl peptidase 4 (DPP-4) inhibitors also attenuate PPH. PPH is one of the factors leading to endothelial dysfunction which is an early event in the pathogenesis of atherosclerosis. Furthermore, DPP-4 inhibitors protect endothelial function through a GLP-1-dependent mechanism. However, the impact of these two types of drugs on endothelial dysfunction in patients with type 2 diabetes has not been fully elucidated. We compared the effects of sitagliptin, a DPP-4 inhibitor, and voglibose, an alpha GI, on endothelial function in patients with diabetes. We conducted a randomized prospective multicenter study in 66 patients with type 2 diabetes who did not achieve the treatment goal with sulfonylurea, metformin or pioglitazone treatment; 31 patients received sitagliptin treatment and 35 patients, voglibose treatment. The flow-mediated dilatation (FMD) of the brachial artery was measured in the fasting state at baseline and after 12 weeks of treatment. The primary endpoint was a change in FMD (ΔFMD) from the baseline to the end of follow-up. The effects of sitagliptin and voglibose on FMD were assessed by ANCOVA after adjustment for the baseline FMD, age, sex, current smoking, diabetes duration and body mass index. Secondary efficacy measures included changes in HbA1c, GIP, GLP-1, C-peptide, CD34, lipid profile, oxidative stress markers, inflammatory markers and eGFR and any adverse events. ΔFMD was significantly improved after 12 weeks of treatment in both groups, and there was no significant difference in ΔFMD between the two groups. There were no significant differences in changes in HbA1c, GIP, GLP-1, C-peptide, lipid profile, oxidative stress marker, inflammatory marker and eGFR between the two groups. Compared with voglibose, sitagliptin significantly increased the circulating CD34, a marker of endothelial progenitor cells. Adverse events were observed in 5 patients in only the voglibose group (diarrhea 1, nausea 1, edema 2 and abdominal fullness 1). Sitagliptin improved endothelial dysfunction just as well as voglibose in patients with type 2 diabetes. Sitagliptin had protective effects on endothelial function without adverse events. registered at http://www.umin.ac.jp/ctrj/ under UMIN000003951
- 30 July 2014
- Published by Springer Nature in Cardiovascular Diabetology
- Vol. 13 (1) , 1-10
Open AccessDPP-4 inhibitor and alpha-glucosidase inhibitor equally improve endothelial function in patients with type 2 diabetes: EDGE study
Alpha glucosidase inhibitor (GI) attenuates postprandial hyperglycemia (PPH) and reduces the risk of cardiovascular events in patients with impaired glucose tolerance or type 2 diabetes. Dipeptidyl peptidase 4 (DPP-4) inhibitors also attenuate PPH. PPH is one of the factors leading to endothelial dysfunction which is an early event in the pathogenesis of atherosclerosis. Furthermore, DPP-4 inhibitors protect endothelial function through a GLP-1-dependent mechanism. However, the impact of these two types of drugs on endothelial dysfunction in patients with type 2 diabetes has not been fully elucidated. We compared the effects of sitagliptin, a DPP-4 inhibitor, and voglibose, an alpha GI, on endothelial function in patients with diabetes. We conducted a randomized prospective multicenter study in 66 patients with type 2 diabetes who did not achieve the treatment goal with sulfonylurea, metformin or pioglitazone treatment; 31 patients received sitagliptin treatment and 35 patients, voglibose treatment. The flow-mediated dilatation (FMD) of the brachial artery was measured in the fasting state at baseline and after 12 weeks of treatment. The primary endpoint was a change in FMD (ΔFMD) from the baseline to the end of follow-up. The effects of sitagliptin and voglibose on FMD were assessed by ANCOVA after adjustment for the baseline FMD, age, sex, current smoking, diabetes duration and body mass index. Secondary efficacy measures included changes in HbA1c, GIP, GLP-1, C-peptide, CD34, lipid profile, oxidative stress markers, inflammatory markers and eGFR and any adverse events. ΔFMD was significantly improved after 12 weeks of treatment in both groups, and there was no significant difference in ΔFMD between the two groups. There were no significant differences in changes in HbA1c, GIP, GLP-1, C-peptide, lipid profile, oxidative stress marker, inflammatory marker and eGFR between the two groups. Compared with voglibose, sitagliptin significantly increased the circulating CD34, a marker of endothelial progenitor cells. Adverse events were observed in 5 patients in only the voglibose group (diarrhea 1, nausea 1, edema 2 and abdominal fullness 1). Sitagliptin improved endothelial dysfunction just as well as voglibose in patients with type 2 diabetes. Sitagliptin had protective effects on endothelial function without adverse events. registered at http://www.umin.ac.jp/ctrj/ under UMIN000003951
- 1 July 2002
- Vol. 40 (1) , 11-7
Multi-focus setting improves the heterogeneity of myocardial opacification in intravenous contrast echocardiography.
Myocardial contrast echocardiography observes heterogeneous opacification between regions near and far from the transducer depending on the depth of the focus point. The efficacy of the multi-focus setting was investigated for the improvement of this heterogeneous opacification of the myocardium in myocardial contrast echocardiography. Myocardial contrast echocardiography was performed in five closed-chest dogs using triggered (every fourth cardiac cycle) second harmonic technology (1.8/3.6 MHz) following intravenous injection of 0.1 ml of Optison. The short-axis view of the left ventricle was recorded and baseline subtracted video intensity (peak intensity) was calculated in the anterior, septal and posterior left ventricular walls to evaluate myocardial opacification. Three different single foci at near (2 cm), middle (4 cm), and far (6 cm) points were examined, as well as the multi-focus setting combining the near and far foci. Using any single focus point, the peak intensities of segments far from the focus points were decreased and heterogeneous myocardial opacification was observed. Only the multi-focus setting demonstrated absence of differences in peak intensities between each segment with sufficient myocardial opacification of all segments. The multi-focus setting may be advantageous for improving the heterogeneity of myocardial opacification in myocardial contrast echocardiography.
- 1 July 2002
- Vol. 40 (1) , 11-7
Multi-focus setting improves the heterogeneity of myocardial opacification in intravenous contrast echocardiography.
Myocardial contrast echocardiography observes heterogeneous opacification between regions near and far from the transducer depending on the depth of the focus point. The efficacy of the multi-focus setting was investigated for the improvement of this heterogeneous opacification of the myocardium in myocardial contrast echocardiography. Myocardial contrast echocardiography was performed in five closed-chest dogs using triggered (every fourth cardiac cycle) second harmonic technology (1.8/3.6 MHz) following intravenous injection of 0.1 ml of Optison. The short-axis view of the left ventricle was recorded and baseline subtracted video intensity (peak intensity) was calculated in the anterior, septal and posterior left ventricular walls to evaluate myocardial opacification. Three different single foci at near (2 cm), middle (4 cm), and far (6 cm) points were examined, as well as the multi-focus setting combining the near and far foci. Using any single focus point, the peak intensities of segments far from the focus points were decreased and heterogeneous myocardial opacification was observed. Only the multi-focus setting demonstrated absence of differences in peak intensities between each segment with sufficient myocardial opacification of all segments. The multi-focus setting may be advantageous for improving the heterogeneity of myocardial opacification in myocardial contrast echocardiography.